Also found in: Wikipedia.


a synthetic corticosteroid used topically as the diacetate salt in the treatment of inflammation and pruritus in certain dermatoses.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.




Therapeutic: anti inflammatories steroidal
Pharmacologic: corticosteroids
Pregnancy Category: C


Management of inflammation and pruritis associated with various allergic/immunologic skin problems.


Suppresses normal immune response and inflammation.

Therapeutic effects

Suppression of dermatologic inflammation and immune processes.


Absorption: Minimal. Prolonged use on large surface areas, application of large amounts, or use of occlusive dressings may increase systemic absorption.
Distribution: Remains primarily at site of action.
Metabolism and Excretion: Usually metabolized in skin.
Half-life: Unknown.

Time/action profile (response depends on condition being treated)



Contraindicated in: Hypersensitivity or known intolerance to corticosteroids or components of vehicles (ointment or cream base, preservative, alcohol); Untreated bacterial or viral infections.
Use Cautiously in: Hepatic dysfunction; Diabetes mellitus, cataracts, glaucoma, or tuberculosis (use of large amounts of high-potency agents may worsen condition); Patients with pre-existing skin atrophy; Obstetric / Lactation / Pediatric: Chronic high-dose usage may result in adrenal suppression in mother, growth suppression in children; children may be more susceptible to adrenal and growth suppression.

Adverse Reactions/Side Effects


  • allergic contact dermatitis
  • atrophy
  • burning
  • dryness
  • edema
  • folliculitis
  • hypersensitivity reactions
  • hypertrichosis
  • hypopigmentation
  • irritation
  • maceration
  • miliaria
  • perioral dermatitis
  • secondary infection
  • striae


  • adrenal suppression (use of occlusive dressings, long-term therapy)


Drug-Drug interaction

None significant.


Topical (Adults) Apply to affected area(s) 1–4 times daily (depends on condition being treated).
Topical (Children) Apply to affected area(s) once daily.

Availability (generic available)

Cream: 0.05%
Ointment: 0.05%

Nursing implications

Nursing assessment

  • Assess affected skin before and daily during therapy. Note degree of inflammation and pruritus. Notify health care professional if symptoms of infection (increased pain, erythema, purulent exudate) develop.
  • Lab Test Considerations: Periodic adrenal function tests may be ordered to assess degree of hypothalamic-pituitary-adrenal (HPA) axis suppression in chronic topical therapy if suspected. Children and patients with dose applied to a large area, using an occlusive dressing, or using high-potency products are at highest risk for HPA suppression.
    • May cause increased serum and urine glucose concentrations if significant absorption occurs.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Side Effects)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Choice of vehicle depends on site and type of lesion. Ointments are more occlusive and preferred for dry, scaly lesions. Creams should be used on oozing or intertriginous areas, where the occlusive action of ointments might cause folliculitis or maceration. Creams may be preferred for aesthetic reasons even though they may be more drying to skin than ointments.
  • Topical: Apply ointment orcream sparingly as a thin film to clean, slightly moist skin. Wear gloves. Apply occlusive dressing only if specified by physician or other health care professional.

Patient/Family Teaching

  • Instruct patient on correct technique of medication administration. Emphasize importance of avoiding the eyes. If a dose is missed, it should be applied as soon as remembered unless almost time for the next dose.
  • Caution patient to use only as directed. Avoid using cosmetics, bandages, dressings, or other skin products over the treated area unless directed by health care professional.
  • Advise parents of pediatric patients not to apply tight-fitting diapers or plastic pants on a child treated in the diaper area; these garments work like an occlusive dressing and may cause more of the drug to be absorbed.
  • Advise patient to consult health care professional before using medicine for condition other than indicated.
  • Instruct patient to inform health care professional if symptoms of underlying disease return or worsen or if symptoms of infection develop.
  • Caution women that medication should not be used extensively, in large amounts, or for protracted periods if they are pregnant or planning to become pregnant.

Evaluation/Desired Outcomes

  • Resolution of skin inflammation, pruritus, or other dermatologic conditions.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Very High Potency Augmented betamethasone dipropionate Clobetasol propionate Diflorasone diacetate Halobetasol propionate II.
TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis: effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines.
Other products that were cleared for marketing in 1999 include diflorasone diacetate ointment USP 0.05% and betamethasone dipropionate ointment USP 0.05%.
Food and Drug Administration (FDA) approving its Abbreviated New Drug Application (ANDA) for Diflorasone Diacetate Cream USP, 0.05%.
Taro's Diflorasone Diacetate Cream is a high-potency topical corticosteroid indicated for the treatment of moderate to severe dermatologic conditions.
"Taro's May 1999 approval for Diflorasone Diacetate Ointment USP, 0.05%, combined with this most recent approval, further expands Taro's extensive line of topical corticosteroid products and reinforces Taro's position as a leading developer, manufacturer and marketer of quality generic creams and ointments," stated Barrie Levitt, M.D., chairman of the company.
The lesion gradually resolved after several weeks of treatment with topical diflorasone diacetate, Several months later the patient dyed the hair around her forehead and developed an erythematous pruritic eruption reminiscent of her reaction to the henna tattoo.
A new dosage form of di-florasone diacetate joins Fougera's diflorasone diacetate cream USP, which was introduced one year ago.
They are: diflorasone diacetate cream USP 0.05% and ointment USP 0.05%; betamethasone dipropionate ointment USP, augmented 0.05%; hydrocortisone lotion USP 1% and hydrocortisone 1% scalp liquid USP; and clobetasol propionate solution, USP 0.05%.
New product introductions in the last two years have been a main driver of Taro's growth, with a number of drugs getting FDA clearance in just the past 12 months, including the topical corticosteroids diflorasone diacetate ointment (the generic equivalent of Dermik Laboratories Inc.'s Psorcon); fluocinonide ointment (a generic version of Medicis The Dermatology Co.'s Lidex); clobetasol propionate gel (a generic form of Glaxo Wellcome Inc.'s Temovate); and hydrocortisone valerate cream and ointment (the generic equivalent of Westwood-Squibb Pharmaceuticals Inc.'s Westcort); and such solid dosage forms as the aforementioned warfarin sodium tablets and ketoconazole tablets (a generic equivalent to Janssen Pharmaceutica Inc.'s Nizoral).
Last year it debuted desoximetasone ointment, diflorasone diacetate cream USP, hydrocortisone scalp liquid and hydrocortisone 1% lotion.
Among the latest abbreviated new drug applications for which Fougera has received approval from the Food and Drug Administration is diflorasone diacetate cream, which is equivalent to Dermik Laboratories Inc.'s Psorcon.